HYHakki Yilmaz

Hakki Yilmaz

*This is an algorithmically generated author record based on publicly available information.

Hakki Yilmaz has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Akcay

    B Department of Internal Medicine , Turgut Ozal University School of Medicine , Ankara , Turkey

    7 shared publications
  • Mukadder Ayse Bilgic

    B Department of Internal Medicine , Turgut Ozal University School of Medicine , Ankara , Turkey

    6 shared publications
  • A. Akcay

    Department of Internal Medicine, Turgut Ozal University School of Medicine, Ankara, Turkey

    5 shared publications
  • Nuket Bavbek

    Department of Internal Medicine, Section of Nephrology, School of Medicine, Turgut Ozal University, Ankara, Turkey

    5 shared publications
  • Tahir Darçın

    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey

    5 shared publications
  • Mustafa Kaya

    4 shared publications

Latest Publications

  • Open Access

    Circulating irisin levels reflect visceral adiposity in non-diabetic patients undergoing hemodialysis

    by Hakki Yilmaz, Muzaffer Cakmak, Tahir Darcin, Osman Inan, Enes Sahiner, Canan Demir, Aynur Aktas, Mukadder Ayse Bilgic, Ali Akcay

    Background: Recent evidence suggests that increased visceral adiposity is a strong independent risk factor for cardiovascular death and all-cause mortality in hemodialysis (HD) patients. Irisin, which is a novel myokine, can play critical roles in diabetes and adiposity. The purpose of our study was to investigate whether serum irisin levels are associated with body mass index, waist circumference (WC), and total fat mass in non-diabetic patients undergoing maintenance HD. Methods: This cross-sectional study included 108 non-diabetic HD patients and 40 age- and sex-matched apparently healthy subjects. Serum irisin concentrations were determined using an enzyme-linked immunosorbent assay. Body fat composition (TBF-410 Tanita Body Composition Analyzer) was measured and calculated. Results: Serum irisin levels did not differ between HD patients and the healthy controls (523.50 ± 229.32 vs. 511.28 ± 259.74, p = 0.782). Serum irisin levels were associated with age (r = 0.314; p =0.006), HOMA-IR (r = 0.472; p = 0.003), WC (r = 0.862; p < 0.001), and total fat mass (r = 0.614; p < 0.001). In multivariate regression analysis, WC (β = 1.240, p < 0.001) and total fat mass (β = 0.792, p = 0.015) were the variables that were significantly associated with irisin concentrations (R2 = 0.684, p < 0.001) after adjusting for confounding factors (age and HOMA-IR). Conclusions: These results suggest that serum irisin levels are related to visceral adiposity in non-diabetic HD patients.


  • Open Access

    Role of interlekin-35 as a biomarker in patients with newly diagnosed Hashimoto’s thyroiditis

    by Hakki Yilmaz, M. Cakmak, B. Ceydilek, C. Demir, A. Aktas

    Objective. Interleukin-35 (IL-35), an interleukin-12 (IL-12) cytokine family member, is shown to be a potent immunosuppressive and anti-inflammatory cytokine. Inducible regulatory T cells (Tregs) produce IL-35 that mediates the immune inhibitory function of Tregs. Growing evidence revealed that upregulation of IL-35 expression may play a critical role in the prevention of autoimmune diseases in various experimental autoimmunity models and vice versa. Hashimoto’s thyroiditis (HT) is considered to be a Treg cell-related autoimmune disease with loss of self-tolerance. Methods. One hundred-twenty eight subjects, newly diagnosed hypothyroid HT patients [56 overt (Group 1), 72 subclinical hypothyroid (Group 2)] and 38 healthy controls (Group 3) were enrolled in the study. The levels of serum IL-35 were determined by enzyme-linked immunosorbent assay (ELISA). Results. Serum IL-35 levels were lower in the HT group when compared with subclinical HT group [304.5 (834.6) pg/ml vs. 636.1 (1542.0) pg/ml, p=0.004] and control cases [304.5 (834.6) pg/ml vs. 1064.7 (2526.8) pg/ml, p<0.001]. Serum IL-35 levels were inversely associated with thyroid stimulating hormone (TSH; rs=-0.396, p<0.001) and anti-thyroid peroxidase antibodies (TPOAb; rs=-0.571, p<0.001) in whole group. Serum IL-35 were negatively associated with TSH (rs=-0.264, p=0.003) and TPOAb (rs=-0.735, p<0.001) in patients with Hashimoto’s thyroiditis (Group 1 + Group 2). Conclusion. The results suggest that IL-35 may play a role in the pathogenesis of HT.


  • Can Serum Gdf-15 be Associated with Functional Iron Deficiency in Hemodialysis Patients?

    by Hakki Yilmaz, Muzaffer Cakmak, Tahir Darcin, Osman Inan, Mukadder Ayse Bilgic, Nuket Bavbek, Ali Akcay

    Functional iron deficiency (FID) incidence is gradually increasing in hemodialysis (HD) patients. Recently, high levels of GDF-15 supressed the iron regulatory protein hepcidin and GDF-15 expression increased in iron-deficient patients. The relationship between FID, GDF-15, and hepcidin is currently unknown. The present study aimed to evaluate the association between GDF-15, hepcidin, and FID in chronic HD patients. Serum GDF-15 and hepcidin concentrations were measured in 105 HD patients and 40 controls. FID is defined as serum ferritin >800 ng/mL, TSAT <25 %, Hb levels <11 g/dL, and reticulocyte haemoglobin content (CHr) <29 pg. Serum GDF-15 and hepcidin levels were increased significantly in HD patients with FID, compared to HD patients without anemia and controls. GDF-15 correlated with ferritin, hepcidin, and CRP in the entire cohort. GDF-15 was related to ferritin and CRP in HD patients with FID. GDF-15 is better diagnostic marker than hepcidin for detection of FID [AUC = 0.982 (0.013) versus AUC = 0.921 (0.027); P = 0.0324]. GDF-15 appears to be a promising tool for detection of FID. High levels of ferritin and CRP correlated with GDF-15. Our results support GDF-15 as a new mediator of FID via hepcidin, chronic inflammation, or unknown pathways.


  • Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients

    by Ozgul Malcok Gurel, Hakki Yilmaz, Tugrul H. Celik, Muzaffer Cakmak, Mehmet Namuslu, Ayse M. Bilgiç, Nuket Bavbek, Ali Akcay, Beyhan Eryonucu

    Galectin-3 (gal-3) is an emerging prognostic biomarker in heart failure (HF). Clinical and experimental studies suggest that gal-3 is an important mediator of HF. Here we aimed to examine the relationship between gal-3 and diastolic dysfunction in patients undergoing maintenance hemodialysis (HD). We examined the relationship between plasma gal-3 levels and left ventricular diastolic function. Plasma gal-3 was measured in 87 subjects with chronic HD and in 45 healthy controls using biochemical evaluations. Conventional echocardiography and pulsed tissue Doppler assessment were performed in all patients. Left ventricular diastolic dysfunction (LVDD) was defined as E’ < 8 cm/s. The E/E’ ratio was used as the main determinant of LVDD grade. The mean gal-3 concentrations were: 16.05 ng/ml (13.89–19.75) in healthy controls; 14.54 ng/ml (10.85–17.65) in HD patients with normal diastolic function; and 23.30 ng/ml (20.12–26.87) in HD patients with LVDD (p < 0.01). Plasma gal-3 levels correlated with E/E’ (r = 0.933, p < 0.01), left atrial volume index (r = 0.713, p < 0.01), and E’ (r = -0.685, p < 0.01). ROC analysis showed that the best gal-3 cut-off point for the diagnosis of LVDD was 20.12 ng/ml with a sensitivity of 67.6 % and specificity of 84.6 % (AUC = 0.803). We suggest that gal-3 may be a promising biomarker for the detection of LVDD in HD patients. Galectin-3 (gal-3) stellt einen prognostischen Biomarker mit zunehmender Bedeutung bei Herzinsuffizienz dar. Klinischen und experimentellen Studien zufolge ist gal-3 wohl ein entscheidender Mediator der Herzinsuffizienz. In der vorliegenden Studie bestand das Ziel darin, den Zusammenhang zwischen gal-3 und diastolischer Dysfunktion bei Patienten unter Erhaltungshämodialyse (HD) zu untersuchen. Die Autoren untersuchten die Beziehung zwischen gal-3-Spiegeln im Plasma und linksventrikulärer Funktion. gal-3 im Plasma wurde bei 87 Teilnehmern mit chronischer HD und 45 gesunden Kontrollen anhand biochemischer Untersuchungen gemessen. Eine konventionelle Echokardiographie und die Untersuchung mit gepulstem Gewebsdoppler erfolgten bei sämtlichen Patienten. Eine linksventrikuläre diastolische Dysfunktion (LVDD) wurde definiert als E’ < 8 cm⁄s. Die E/E’-Ratio stellte das Hauptkriterium für den Grad der LVDD dar. Die durchschnittliche gal-3-Konzentration betrug 16,05 ng/ml (13,89–19,75) bei den gesunden Kontrollen; 14,54 ng/ml (10,85–17,65) bei HD-Patienten mit normaler diastolischer Funktion und 23,30 ng/ml (20,12–26,87) bei HD-Patienten mit LVDD (p < 0,01). Die Plasma-gal-3-Spiegel korrelierten mit E/E’ (r = 0,933; p < 0,01), LAVI (r = 0,713; p < 0,01) und E’ (r = -0,685; p < 0,01). Die ROC-Analyse zeigte, dass der beste gal-3-Grenzwert für die Diagnose einer LVDD bei 20,12 ng/ml lag – mit einer Sensitivität von 67,6 % und einer Spezifität von 84,6 % (AUC: 0,803). Die Autoren schätzen gal-3 als vielversprechenden Biomarker zur Erkennung einer LVDD bei HD-Patienten ein.


  • Elevated Plasma Levels of Betatrophin in Women with Gestational Diabetes Mellitus

    by H. Yilmaz, M. Cakmak, T. Darcin, C. Demir, O. Inan, B. Ceydilek, Y. Onaran, N. Bavbek, M. A. Bilgic, A. Akcay

    Article Retraction Due to serious scientific misconduct and an attempt at double publication, Thieme Publishers and the Editors-in-Chief of “Experimental and Clinical Endocrinology & Diabetes" retract, with immediate effect, the following article: Yilmaz H, Cakmak M, Darcin T, Demir C, Inan O, Ceydilek B, Onaran Y, Bavbek N, Bilgic MA, Akcay A: Elevated Plasma Levels of Betatrophin in Women with Gestational Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2015 May 6. [Epub ahead of print]


  • Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor?

    by H. Yilmaz, M. Cakmak, O. Inan, T. Darcin, A. Akcay

    Galectin-3 (Gal-3) is a marker of cardiac fibrosis and predicts incident heart failure. Gal-3-deficient mice are resistant to multiple low-dose streptozotocin-induced diabetes. Recent experimental studies suggested an important role for Gal-3 in the regulation of adiposity, metaflammation and type 2 diabetes. This study aimed to examine the relationship between Gal-3 and newly diagnosed prediabetes and diabetes. Gal-3 concentrations were measured in 118 participants and 56 age- and sex-matched healthy controls. All subjects underwent a 75-g oral glucose tolerance test and were stratified into normal, prediabetic, and diabetes mellitus subgroups. DM was defined as a plasma glucose level ≥126 mg/dL in the fasting state or ≥200 mg/dL in the second hour after glucose loading. Impaired fasting glucose was defined as an FPG level of 100–125 mg/dL, and impaired glucose tolerance was defined as a 2-h plasma glucose level of 140–199 mg/dL. Sixty-one patients had prediabetes (Group 1), 57 had diabetes (Group 2), and 56 had neither diabetes nor prediabetes (Group 3). Gal-3 levels correlated with FPG (r = 0.787, P < 0.01), 2hPG (r = 0.833, P < 0.01), CRP (r = 0.501, P < 0.01), and HOMA-IR (r = 0.518, P < 0.01). Gal-3 levels were higher in Group 2 than in Groups 1 and 3 [1,053.9 (358.1) and 744.1 (119.3) vs. 481.7 (175.4) pg/mL; P < 0.001]. Gal-3 is an independent predictor of diabetes in multivariate logistic analysis. In ROC analysis, a Gal-3 cutoff value of 803.55 pg/mL diagnoses diabetes with a sensitivity of 80.7 % and a specificity of 85.5 % (AUC = 0.912). Gal-3 is a promising biomarker for detecting prediabetes and diabetes.


  • Increased serum levels of GDF-15 associated with mortality and subclinical atherosclerosis in patients on maintenance hemodialysis

    by H. Yilmaz, H.T. Çelik, O.M. Gurel, M.A. Bilgic, M. Namuslu, H. Bozkurt, A. Ayyildiz, O. Inan, N. Bavbek, A. Akcay

    Increased carotid intima–media thickness (CIMT) was shown to be an independent predictor of cardiovascular (CV) mortality in dialysis patients and the general population. Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor superfamily, is produced by cardiomyocytes and atherosclerotic lesions under stress conditions such as inflammation. We assessed associations between serum concentrations of GDF-15, mortality, and CIMT for subclinical atherosclerosis in hemodialysis (HD) patients. A total of 87 patients on maintenance hemodialysis and 45 sex- and age-matched healthy controls were included in this prospective study. Serum GDF-15 levels were measured by ELISA. CIMT was assessed by Doppler ultrasonography. The association between serum GDF-15 levels and mortality was assessed using Cox regression analysis with serum levels categorized into two groups according to the median value (328.18 pg/ml). Patients were followed for 2 years and cause-specific and all-cause mortality were determined. The median level of serum GDF-15 was significantly higher in HD patients than controls [328 (198–522) vs. 176 (101–289) pg/ml, p < 0.01, respectively]. Serum GDF-15 levels were correlated to CIMT (r = 0.607, p < 0.001), C-reactive protein (CRP; r = 0.250, p = 0.010), HD duration (r = 0.376, p = 0.004), and serum albumin (r = − 0.156, p = 0.030). The multivariate analysis revealed that GDF-15 was found to be an independent variable of CIMT in HD patients. In the study, the serum GDF-15 level was an independent marker of all-cause of mortality when adjusted for age, CRP, and history of diabetes mellitus. The relationship between serum GDF-15, mortality, and carotid artery thickening suggests that GDF-15 may be a novel marker of atherosclerosis, inflammation, and malnutrition in HD patients. Eine erhöhte Intima-Media-Dicke der A. carotis (CIMT) ist nachgewiesen als unabhängiger Prädiktor der kardiovaskulären Mortalität, sowohl bei Hämodialyse(HD-)Patienten als auch der Allgemeinbevölkerung. Der Wachstumsdifferenzierungsfaktor 15 (GDF-15) aus der TGF(„transforming growth factors“)-Superfamilie wird von Kardiomyozyten und in atherosklerotischen Läsionen unter Stressbedingungen gebildet, z. B. bei Inflammation. Bestimmt wurden Assoziationen zwischen GDF-15-Serumkonzentrationen, Mortalität und CIMT für eine subklinische Atherosklerose bei Hämodialysepatienten. Insgesamt wurden 87 Dauer-HD-Patienten und 45 geschlechts- und altersgematchte Kontrollprobanden in die prospektive Studie aufgenommen. Die GDF-15-Serumkonzentrationen wurden per ELISA bestimmt, die CIMT mit Dopplersonographie. Assoziationen zwischen Serum-GDF-15-Konzentrationen und Mortalität wurden überprüft mittels Cox-Regressionsanalyse. Ausgehend vom Median (328,18 pg/ml) wurden 2 Gruppen gebildet. Die Follow-up-Phase war 2 Jahre lang, ermittelt wurden krankheitsspezifische wie generelle Mortalität. Die mediane Konzentration von GDF-15 im Serum war bei HD-Patienten im Vergleich mit den Kontrollen signifikant höher [328 (198–522) vs. 176 (101–289) pg/ml, p < 0,01]. Korreliert mit Serum-GDF-15-Konzentrationen wurden C-reaktives Protein (CRP; r = 0,250, p = 0,010), Dauer der Dialyse (r = 0,376, p = 0,004) und Albuminkonzentration im Serum (r = − 0,156, p = 0,030). In der multivariaten Analyse erwies sich GDF-15 als eine unabhängige Variable für CIMT bei HD-Patienten. Ferner war die Serum-GDF-15-Konzentrationen nach Adjustierung für Alter, CRP und Diabetes-mellitus-Anamnese ein unabhängiger Marker für Mortalität allgemein. Die Beziehung zwischen GDF-15-Serumkonzentrationen, Mortalität und erhöhter CIMT weist darauf hin, dass GDF-15 ein innovativer Marker für Atherosklerose, Inflammation und Mangelernährung bei HD-Patienten sein könnte.


  • Relationship between late arteriovenous fistula (AVF) stenosis and neutrophil–lymphocyte ratio (NLR) in chronic hemodialysis patients

    by Hakki Yilmaz, Alper Bozkurt, Muzaffer Cakmak, Huseyin Tugrul Celik, Mukadder Ayse Bilgic, Nuket Bavbek, Ali Akcay

    Objectives: Primary cause of late arteriovenous fistula (AVF) dysfunction is venous stenosis as result of neointimal hyperplasia. The mechanism of AVF stenosis is not exactly understood. But inflammation is a contributing factor for development of AVF stenosis. Neutrophil–lymphocyte ratio (NLR) reflects systemic inflammation, and it was investigated in many diseases. The aim of this study was to investigate the relationship between NLR and AVF stenosis in chronic hemodialysis patients. Materials and methods: Of 593 patients applied to the department of interventional radiology between January 2011 and November 2012, a total of 108 patients meeting the appropriate criteria were included in this study. All patients were assessed with Color Doppler ultrasonography and then digital subtraction angiography was used for the patients with abnormal results. Sixty-four patients were classified as patients with AVF stenosis (group 1) and 44 patients without AVF stenosis (group 2). Routine biochemical and complete blood count values measured six months ago were recorded for all patients. Results: Mean NLR (3.47 ± 0.46 vs. 2.27 ± 0.22; p < 0.001) was higher in group 1 compared to group 2, whereas high-density lipoprotein (HDL; 31.8 ± 12.6 mg/dL vs. 51.5 ± 11.9 mg/dL; p < 0.001) was lower in group 1. NLR level was correlated with degree of AVF stenosis (r = 0.625; p < 0.01). Receiver operating characteristic curve analysis showed that NLR (optimal-cut-off = 2.70) was a useful parameter in prediction of AVF stenosis (AUC = 0.893, sensitivity = 98.4% and specificity = 75%; p < 0.001). NLR level and HDL < 30 mg/dL in logistic regression analysis are independent predictors of AVF stenosis. Conclusions: For hemodialysis patients with increased level of NLR and decreased level of HDL, regular monitoring with regard to the development of AVF stenosis may be beneficial. Our study suggests that the mechanism of AVF stenosis might have similarities to that of atherosclerosis.


  • Serum galectin-3 levels were associated with proteinuria in patients with Familial Mediterranean Fever

    by Hakki Yilmaz, Osman Inan, Tahir Darcin, Mukadder Ayse Bilgic, Ali Akcay

    The most common and pernicious complication of Familial Mediterranean fever (FMF) is renal amyloidosis, usually affecting the kidneys, leading to end-stage renal failure. FMF-related renal amyloidosis needed to be diagnosed early. Optimal colchicine dose is effective in preventing and reversing renal amyloidosis. Galectin-3, profibrotic mediator, has regulatory functions in inflammation, fibrosis and tumorigenesis. Galectin-3 is a strong prognostic marker for heart failure. Galectin-3 plays role in diabetic nephropathy and chronic kidney disease. The aim of the study is to investigate whether galectin-3 is related to proteinuria and amyloidosis in FMF. Seventy-five FMF patients who have no exclusion criteria and healthy controls (n = 36) were included. Serum galectin-3 was measured and morning spot urine was collected for determination of the protein/creatinine ratio (PCR). Serum Galectin-3 levels were significantly higher in FMF patients than the control group [969.66 (3825) pg/mL vs. 238 (921) pg/mL, respectively; Pn = 48) had FMF patients with proteniuria, Group2 (n = 27) had FMF patients without proteinuria. Group1 had higher levels of galectin-3 than Group2 [1106(3812) pg/mL vs. 867.3(1433) pg/mL, P < 0.001]. Galectin-3 levels were correlated with PCR in whole group and FMF group (r = 0.785, P < 0.001 and r = 0.803, P < 0.001). In ROC curve, best cutoff value = 581.50 pg/mL was used to detect proteinuria (sensitivity = 91.7 %, specificity = 71.4 %, AUC = 0.879) and optimal cutoff value = 1458.00 pg/mL was an indicator of nephrotic-range proteinuric (sensitivity = 100 %, specificity = 92.1 %, AUC = 0.983). Galectin-3 is associated with proteinuria and renal amyloidosis in FMF. Galectin-3 may play role in pathogenesis of amyloidosis.